<?xml version="1.0" encoding="UTF-8"?>
<p>Fusarithioamide B 
 <bold>389</bold> has been assessed for antibacterial activities towards various microbial strains (
 <italic>Staphylococcus aureus</italic> (AUMC No. B-54) and 
 <italic>Bacillus cereus</italic> (AUMC No. B-5) as Gram-positive bacteria, 
 <italic>Escherichia coli</italic> (AUMC No. B-53), 
 <italic>Pseudomonas aeurginosa</italic> (AUMC No. B-73), and 
 <italic>Serratia marscescens</italic> (AUMC No. B-55) as Gram-negative bacteria) by disc diffusion assay. It possessed high antibacterial potential towards 
 <italic>E. coli</italic> (Inhibition zone diameter (IZD): 25.1 ± 0.60 mm, MIC value: 3.7 ± 0.08 µg/mL), 
 <italic>B. cereus</italic> (Inhibition zone diameter (IZD): 23.0 ± 0.36 mm, MIC value: 2.5 ± 0.09 µg/mL), and 
 <italic>S. aureus</italic> (Inhibition zone diameter (IZD): 17.4 ± 0.09 mm, MIC value: 3.1 ± 0.11 µg/mL) compared to ciprofloxacin used as antibacterial standard (Inhibition zone diameter (IZD): 15.3 ± 0.07 mm, MIC value: 3.4 ± 0.32 µg/mL for 
 <italic>S. aureus</italic>, Inhibition zone diameter (IZD): 21.2 ± 0.51 mm, MIC value: 2.9 ± 0.20 µg/mL for 
 <italic>B. cereus</italic>, Inhibition zone diameter (IZD): 25.6 ± 0.22 mm, MIC value: 3.9 ± 0.06 µg/mL for 
 <italic>E. coli</italic>) [
 <xref rid="B125-ijms-22-00959" ref-type="bibr">125</xref>].
</p>
